Analysts See $-0.88 EPS for Sarepta Therapeutics Inc (SRPT)

October 13, 2017 - By Henry Gaston

 Analysts See $ 0.88 EPS for Sarepta Therapeutics Inc (SRPT)
Investors sentiment increased to 1.52 in 2017 Q2. Its up 0.09, from 1.43 in 2017Q1. It increased, as 19 investors sold Sarepta Therapeutics Inc shares while 41 reduced holdings. 30 funds opened positions while 61 raised stakes. 41.29 million shares or 4.20% more from 39.62 million shares in 2017Q1 were reported.
10,540 are owned by Raymond James And. 813,968 are owned by Goldman Sachs Gru. Legal And General Gru Plc reported 17,590 shares stake. Blair William And Il holds 0% or 17,025 shares. Samlyn Capital Limited accumulated 161,300 shares. Camber Mngmt Limited has 1.30M shares. Raymond James Financial Services Advsr, Florida-based fund reported 20,871 shares. Morgan Stanley holds 0% or 178,184 shares in its portfolio. Nationwide Fund Advsr stated it has 0% in Sarepta Therapeutics Inc (NASDAQ:SRPT). Hightower Ltd Liability Co reported 53,477 shares or 0.02% of all its holdings. Comml Bank Of Montreal Can owns 98,775 shares or 0% of their US portfolio. Tourbillon Capital Prtn Lp has invested 1.25% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT). Ameritas Invest Prns Inc holds 0.01% or 4,561 shares in its portfolio. United Cap Fincl Advisers Lc holds 0.01% or 25,458 shares. Qs Investors Lc has invested 0% in Sarepta Therapeutics Inc (NASDAQ:SRPT).

Investors wait Sarepta Therapeutics Inc (NASDAQ:SRPT) to report on October, 26. its quarterly earnings Wall Street analysts expect $-0.88 EPS, up $0.22 or 20.00 % from last year’s $-1.1 same quarter earnings. Sarepta Therapeutics Inc’s Wall Street analysts see -23.48 % EPS growth, taking into account the $-1.15 EPS reproted in the previous quarter, The stock increased 0.21% or $0.11 during the last trading session, reaching $51.28. About 1.51M shares traded. Sarepta Therapeutics Inc (NASDAQ:SRPT) has risen 96.82% since October 13, 2016 and is uptrending. It has outperformed by 80.12% the S&P500.

Sarepta Therapeutics Inc (NASDAQ:SRPT) Ratings Coverage

Among 26 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 19 have Buy rating, 1 Sell and 6 Hold. Therefore 73% are positive. Sarepta Therapeutics had 88 analyst reports since August 5, 2015 according to SRatingsIntel. Janney Capital upgraded the shares of SRPT in report on Monday, September 19 to “Buy” rating. The rating was maintained by Needham on Wednesday, February 22 with “Buy”. The firm has “Buy” rating given on Thursday, July 20 by Oppenheimer. The rating was maintained by RBC Capital Markets with “Buy” on Wednesday, June 21. J.P. Morgan maintained the shares of SRPT in report on Wednesday, September 6 with “Buy” rating. The stock of Sarepta Therapeutics Inc (NASDAQ:SRPT) has “Market Perform” rating given on Thursday, April 21 by William Blair. The rating was upgraded by RBC Capital Markets on Monday, September 19 to “Outperform”. The firm has “” rating by SunTrust given on Friday, August 7. Morgan Stanley maintained the stock with “Equal-Weight” rating in Thursday, July 20 report. On Monday, September 19 the stock rating was upgraded by PiperJaffray to “Overweight”.

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The company has market cap of $3.30 billion. The Firm focuses on the discovery and development of ribose nucleic acid -targeted therapeutics for the treatment of rare neuromuscular diseases. It currently has negative earnings. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

More notable recent Sarepta Therapeutics Inc (NASDAQ:SRPT) news were published by: which released: “Sarepta Therapeutics Appoints Guriqbal S. Basi, Ph.D. as Chief Scientific Officer” on September 25, 2017, also with their article: “Sarepta: Uncertainties And Controversies Surround Its Trials” published on September 28, 2017, published: “Sarepta Therapeutics’ (SRPT) CEO Douglas Ingram Presents at Morgan Stanley …” on September 13, 2017. More interesting news about Sarepta Therapeutics Inc (NASDAQ:SRPT) were released by: and their article: “Sarepta Therapeutics’ (SRPT) CEO Doug Ingram on Baird 2017 Global Healthcare …” published on September 14, 2017 as well as‘s news article titled: “Sarepta shares rise nearly 3% premarket after RBC sees ‘compelling’ argument …” with publication date: October 09, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.